The Patent Finder

Terms ending in 2043

Genmab A/S

Every in-force patent on Genmab A/S's record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,398,214Binding Agents Binding to Epcam and CD137
In force
 · High confidence
BioNTech SEIn forceHigh confidence
US 11,932,693Monoclonal Antibodies Directed Against Programmed DEATH-1 Protein and Their Use in Medicine
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 12,692,320Bispecific Antibodies Against CD3 and CD20
In force
 · Medium confidence
Genmab A/SIn forceMedium confidence
US 12,674,001Method of Treating Cancer by Administering an Antibody Which Binds to 5T4
In force
 · High confidence
Genmab A/SIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Genmab A/S.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited